A simple statistical test to infer the causality of target/phenotype correlation from small molecule phenotypic screens

Bioinformatics

Volumn 28, Issue 3, 2012, Pages 301-305

  Wei, Xin ^a   Hoffman, Ann F ^a   Hamilton, Shannon M ^a   Xiang, Qing ^a   He, Yang ^a   Venus So, W ^a   So, Sung Sau ^a   Mark, David ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE INHIBITOR;

ARTICLE; CELL FREE SYSTEM; CELL SURVIVAL; DRUG DEVELOPMENT; HELA CELL; HIGH THROUGHPUT SCREENING; HUMAN; METHODOLOGY;

CELL SURVIVAL; CELL-FREE SYSTEM; DRUG DISCOVERY; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PROTEIN KINASE INHIBITORS;

EID: 84856579292     PISSN: 13674803     EISSN: 14602059     Source Type: Journal    
DOI: 10.1093/bioinformatics/btr676     Document Type: Article

References (15)

1. Agresti, A. (2002) Categorical Data Analysis. John Wiley & Sons, Inc., Hoboken, New Jersey.
2. Correll, P.H. et al. (2006) Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies. Gene 374, 26-38.
3. Hart, C.P. (2005) Finding the target after screening the phenotype. Drug Discov. Today, 10, 513-519.
4. Hoffman, A.F. and Garippa, R.J. (2007) A pharmaceutical company user's perspective on the potential of high content screening in drug discovery. Methods Mol. Biol., 356, 19-31.
5. Klinghoffer, R.A. et al. (1999) Src family kinases are required for integrin but not PDGFR signal transduction. EMBO J., 18, 2459-2471.
6. Kumar, S. et al. (2004) MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief. Bioinformatics, 5, 150-163.
7. Lennerz, J.K. et al. (2010) Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to hepatic steatosis, and defective gluconeogenesis. Mol. Cell. Biol., 30, 5043-5056.
8. Lu, L. et al. (2008) Aurora A is essential for early embryonic development and tumor suppression. J. Biol. Chem., 283, 31785-31790.
9. SAS Institute Inc (2002) SAS/STAT 9.1 User's Guide. SAS Institute Inc., Cary, NC.
10. Shalaby, F. et al. (1997)Arequirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell, 89, 981-990.
11. Soriano, P et al. (1991) Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell, 64, 693-702.
12. Spring, D.R. (2005) Chemical genetics to chemical genomics: small molecules offer big insights. Chem. Soc. Rev., 34, 472-482.
13. Steeghs, N. et al. (2009) Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J. Clin. Oncol., 27, 5094-5101.
14. Swinney, D.C. and Anthony, J. (2011) How were new medicines discovered? Nat. Rev. Drug Discov., 10, 507-519.
15. Wang, Y. et al. (2010) An overview of the PubChem BioAssay resource. Nucleic Acids Res., 38, D255-D266.